Fed. Circ. Mulls New Trial In Vectura's $107M Inhaler IP Win

Law360 (October 5, 2020, 11:14 PM EDT) -- A Federal Circuit judge peppered Vectura Limited's counsel with tough questioning Monday, suggesting that attorneys for the U.K.-based pharmaceutical company defied a Delaware federal court's instructions during jury trial last year, which may warrant a retrial of the nearly $107 million verdict in an inhaler patent dispute.

Before a three-judge panel is a petition by GlaxoSmithKline LLC and Glaxo Group Ltd. seeking to vacate Vectura's jury trial win in May 2019 finding Glaxo willfully infringed U.S. Patent No. 8,303,991, which covers a method for micro-milling an active compound and an additive material in a combination that promotes the aerosol dispersal of the combined...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!